In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/-0.6%) and in nine age-and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dosedependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. 
Introduction
In normal subjects, oral glucose enhances insulin secretion more than does intravenous glucose infusion (incretin effect; [1] [2] [3] [4] . This augmentation of insulin secretion is due to the secretion and action of gut hormones with insulinotropic activity, namely gastric inhibitory polypeptide (GIP,' also called Address reprint requests to Dr. Nauck, Division of Gastroenterology and Endocrinology, Department of Internal Medicine, Georg-AugustUniversitat, Robert-Koch-Strasse 40, D-3400 Gottingen, FRG.
Receivedfor publication 12 May 1992 and in revisedform 17 August 1992. glucose-dependent insulinotropic hormone; 5, 6) from the upper gut (7) and glucagon-like peptide 1 [7-36 amide] (GLP-1 [7-36 amide] ; proglucagon 78-107 amide; 8-11) from the lower gut (12, 13) . In type-2 diabetic patients, the incretin effect is reduced or lost (4, 14) . This does not seem to be a consequence of deficient release of GIP, in that most studies found a normal or even enhanced secretion of this incretin hormone in type-2 diabetic patients (for review, see references 15 and 16) . According to a recent study, basal plasma concentrations of immunoreactive GLP-1 are higher and responses to oral glucose are greater in type-2 diabetic patients ( 17). By using GIP of the porcine amino acid sequence, several studies have uniformly described a reduced insulinotropic effectiveness in type-2 diabetic patients as compared to normal subjects ( 18, 19) . Human GIP differs by two amino acids (in positions 18 and 34, respectively) from porcine GIP (20, 21 ) . Insulinotropic effects of human GIP in type-2 diabetic patients have not yet been studied. Similarly, no detailed studies comparing insulinotropic actions of GLP-1 [7-36 amide] in type-2 diabetic patients and normal subjects are available. Preliminary results suggest that GLP-1 in pharmacological doses can stimulate insulin secretion in type-2 diabetic patients (22) . In streptozotocin-diabetic rats, on the other hand, the insulinotropic effectiveness of both GIP and GLP-1 [7-36 amide] was reduced (23) .
In the isolated perfused pancreas of the rat, pig, or dog, GLP-1 [7-36 amide] or suppressed pancreatic glucagon concentrations (23) (24) (25) (26) . Except for preliminary data ( 10, 27) , the conditions under which glucagon secretion is regulated by GLP-1 [7-36 amide] in normal humans and type-2 diabetic patients have not been defined.
The present study was designed to compare, at identical plasma glucose concentrations (hyperglycemic clamp experiments), the insulinotropic and glucagon-lowering actions of both synthetic human GIP and GLP-1 [7-36 amide] , infused at both approximately physiological and pharmacological concentrations, in matched groups of type-2 diabetic patients and normal subjects.
Methods
Study protocol. The study protocols were approved by the ethics committee of the medical faculty of the Georg-August-Universitat, Gottingen, on 21 April, 1988 Experimentalprocedures. Each participant took part in four examinations: (a) an oral glucose challenge (75 g/300 ml); (b) a hyperglycemic "clamp" experiment aiming at a capillary plasma glucose concentration of 8.75 mmol/ liter, maintained over 210 min, with the subsequent intravenous bolus injection of glucagon ( 1 mg); (c) a hyperglycemic "clamp" experiment with exogenous synthetic human GIP at an infusion rate resulting, according to prior experience (6, 10, 11) , and 10 min after the glucagon bolus (protocol b) blood was drawn to estimate the acute B cell response. After centrifugation, plasma for hormone analyses was kept frozen at -30°C. Laboratory determinations. Glucose was measured using a glucose analyzer 2 (Beckman Instruments, Inc., Munich, FRG; glucose oxidase method). Plasma IR-insulin and C-peptide were determined using commercial radioimmunoassay kits (Insulin RIA 100, Pharmacia, Freiburg, FRG; RIA-mat C-peptide II, Byk-Sangtec Diagnostika, Dietzenbach, FRG), with human insulin and C-peptide as standard.
IR-GIP was assayed according to Kuzio et al. (29), using antiserum Go 77/ 5, and human GIP (Bissendorf Biochemicals) for tracer preparation and as standard. Intra-and interassay coefficients of variation were 15% and 18%, respectively.
IR-GLP-1 was measured in ethanol-extracted plasma as described by Orskov and Holst (30), using antiserum 2135 (final dilution 1:150,000) and synthetic GLP-l [7-36 amide] (Peninsula Laboratories, St. Helens, UK) for tracer preparation and as standard. This antiserum cross-reacts with equal strength with all peptides containing the proglucagon 78-107 amide sequence, regardless ofamino-or carboxylterminal extensions. Intra-and interassay coefficients ofvariation were < 9% and < 14%, respectively.
Pancreatic glucagon was assayed in ethanol-extracted plasma using antibody 4305 (31 ) .
Calculations and statistical analysis. Person characteristics are shown as mean±SD, and experimental results are reported as mean±SEM.
Integration was carried out according to the trapezoidal rule. Glycemic excursions and secretory responses were analyzed as integrated incremental values over or as reactive excursions below baseline values (glucose, glucagon).
Significances of differences were tested using nonparametric tests (Mann-Whitney's U-test for group comparisons and the Wilcoxon signed rank test for paired comparisons). A P value < 0.05 was taken to indicate significant differences.
Results
In type-2 diabetic patients, an oral glucose challenge elicited the typical slow increment in insulin and C-peptide concentrations, whereas the overall integrated incremental responses were not different from those in normal subjects (Fig. 1, B and C).
GIP responses after oral glucose tended to be lower in the type-2 diabetic patients (by 31%, P = 0.10; difference not signif- icant) (Fig. 1 D) . (Fig. 1, A and F) .
Hyperglycemic clamp conditions led to comparable capillary glucose concentrations (-8.75 mmol/liter, coefficient of variation between 2.8±0.3% and 4.8±0.4%) for type-2 diabetic patients and normal subjects throughout the experiments with and without administration of insulinotropic peptide hormones (not shown).
During intravenous infusions of GIP at the lower rate (0.8 pmol kg-' min-'; Fig. 2, A and C) , plasma concentrations were comparable to peak responses after the glucose challenge (Fig. 1 D) , while with the higher infusion rate (2.4 pmol kg-' min-'), clearly supraphysiological concentrations were reached (Fig. 2, A and C) .
With GLP-1 [7-36 amide] infusions at the lower rate (0.4 pmol kg-' min-'; Fig. 2, B and D) , similar plasma concentrations were measured as after endogenous stimulation with oral glucose (Fig. 1 E) . The Both GIP and GLP-1 [ 7-36 amide ] dose-dependently stimulated insulin secretion (insulin and C-peptide) in type-2 diabetic patients and normal subjects ( Fig. 3 ; Table II) . GIP, at the low infusion rate, significantly stimulated insulin secretion, but to a lesser extent (lower C-peptide concentrations) than did oral glucose (Figs. and 3) . The difference between responses in type-2 diabetic patients and normal subjects was not significant (Table II) . With the high rate of GIP infusion, a greater insulin secretory response was elicited in normal subjects, but in type-2 diabetic patients even the pharmacological concentrations of GIP reached ( 1,053±108 pmol/liter) only marginally stimulated insulin secretion. Whereas in normal subjects the glucose infusion had to be increased owing to GIP-stimulated insulin release, the glucose infusion rate hardly had to be increased in type-2 diabetic patients (Table II) . On the other hand, exogenous GLP-1 [7-36 amide] led to significantly higher increments in insulin and C-peptide than GIP at both infusion rates and in both type-2 diabetic patients and normal subjects ( Fig. 3 ; Table II ). At the low and the high dose, the increment in C-peptide concentrations in type-2 diabetic patients was approximately two thirds of the responses in normal subjects (Table II) . The difference between type-2 diabetic patients and normal subjects was not significant. Glucose infusion had to be increased in normal subjects, and, to a lesser extent also in type-2 diabetic patients, in order to maintain a constant glucose concentration during the hyperglycemic clamp experiments (Table II) . At ent between type-2 diabetic patients and normal subjects in the basal state, were suppressed during the hyperglycemic clamp in normal subjects (by 65%, P = 0.012 ), but not in type-2 diabetic patients (P = 0.28; Fig. 4 ). Exogenous GIP was without a major effect on pancreatic glucagon concentrations in normal subjects, whereas GLP-1 [7-36 amide] slightly, but significantly lowered pancreatic glucagon in normal subjects (P = 0.018 and 0.012 for the low and high dose, respectively). This effect was much more prominent in type-2 diabetic pa- tients (Fig. 4 A) . The low infusion rate ofGLP-1 [ 7-36 amide ] led to a 38.6% reduction in glucagon (P = 0.043), and the suppression reached 44.2% (P = 0.046) at the high infusion rate.
Discussion
Among other defects in insulin secretion in type-2 diabetic patients, there is a reduced or absent incretin effect: insulin release is no longer stimulated more by oral as compared to "isoglycemic" intravenous glucose (2, 3, 14) . Due to the magnitude of the incretin effect (in normal subjects it contributes -25-60% to the insulin secretory response after and oral glu- cose challenge, depending on the size of the glucose load; 2-4, 32, 33), its loss may partially be responsible for the diabetic glucose tolerance. Although the incretin effect has not been quantified in the current study, the characteristics ofthe type-2 diabetic patients were sufficiently similar to those studied previously (4) to assume a reduction in the overall incretin effect in them as well. A reduced incretin effect can, in principle, be caused by impaired secretion of relevant incretin hormones or by B cell insensitivity towards their insulinotropic action. Assuming that GIP and GLP-1 [7-36 amide] are the incretin hormones that normally mediate the incretin effect (6, 10, 11) , previous studies do not support that they are released to a lesser extent in type-2 diabetic patients. Only in some of them hyposecretion of GIP occurs ( 16) . Therefore, the slightly reduced GIP response after oral glucose in the present study is compatible with the literature. GLP-1 [7-36 amide] responses in type-2 diabetic patients, in one study, were elevated in comparison to normal subjects ( 17). Using the same radioimmunoassay method, in the present study type-2 diabetic patients had lower incremental responses of immunoreactive GLP-1 than normal subjects (Fig. 1 E) . Therefore, the GLP-1 [7-36 amide] response to oral glucose seems to be as variable as is known in the case of GIP (4, 15, 16) .
Using natural or synthetic GIP of the porcine amino acid sequence, a reduced insulin secretory response has uniformly been described in type-2 diabetic patients ( 18, 19) . The present study confirms that also human GIP, at physiological or even pharmacological concentrations, does not stimulate insulin secretion in type-2 diabetic patients as it does in normal subjects ( Fig. 3 ; Table II ). In young volunteers, GIP appears to mediate a quantitatively major part ofthe incretin effect, because exogenous GIP in concentrations that approximately matched postprandial levels stimulated insulin secretion almost as good as did oral glucose (6, 11, 34) . Compared to our previous study ( 11), which was performed at the same time and using the same lot numbers ofGIP, the insulin secretory response during GIP infusion appears to be smaller in the present group ofolder normal subjects. Although this has to be clarified by direct comparison, this observation is compatible with the hypothesis that the sensitivity of the B cell toward GIP is reduced with aging, as suggested by Elahi et al. (35, 36) . Nevertheless, even if a reduced responsiveness to GIP is a typical phenomenon in normal subjects of the age group studied (Table I) , the insulin secretory response to GIP infusion was further reduced in type-2 diabetic patients.
Insulinotropic effects of GLP-1 [7-36 amide] in man have been reported in normal subjects (10, 11) , and only recently data have been published in type-2 diabetic patients using GLP-1 Judging from immunoreactive GIP responses after oral glucose and during low-dose intravenous infusion, (Figs. 1 and 2) , GIP concentrations tended to be lower with exogenous administration. This may have compensated for the contribution of 8,000-D "GIP," which is not insulinotropic (41) Glucagon secretion has been suppressed by GLP-1 amide] in the isolated perfused pancreas (23) (24) (25) (26) and a small effect has been noted, in the basal state, in healthy volunteers ( 10, 27) . The glucagon-lowering effect of GLP-1 [7-36 amide] was almost lost in the perfused pancreas of streptozotocin-diabetic rats (23) . The present study, in contrast, demonstrates that GLP-1 [7-36 amide] is able to dose-dependently lower pancreatic glucagon in type-2 diabetic patients (Fig. 4) . The degree of suppression was similar to the one reached during hyperglycemia in normal subjects.
The present study, together with previously published data (22, 38) , poses the question whether GLP-1 [7-36 amide] receptor agonists could be used pharmacologically to lower plasma glucose in type-2 diabetic patients. GIP is not suitable for this purpose, because its insulinotropic activity is almost lost in type-2 diabetic patients, even at supraphysiological concentrations (Figs. 2 and 3) . GLP-1 [7-36 amide] may be a better candidate. In favor of this proposition are the well-preserved insulinotropic activity of GLP-1 [7-36 amide] (Fig. 3 ; Table II ), its glucagon-lowering effect (Fig. 4) , and possible inhibitory effects on gastric emptying rates (27, 38) , which would lower the requirement for rapid insulin secretory responses as do other means ofslowing nutrient absorption (45 In conclusion, the reduced incretin effect in type-2 diabetic patients is most likely explained by the reduced insulinotropic effectiveness ofGIP. The plasma concentrations oftrue GLP-1 [7-36 amide] after oral glucose probably are not sufficient to maintain a normal incretin effect in type-2 diabetic patients. However, the well-preserved insulinotropic effect, and the glucagon-lowering potency of GLP-1 [7-36 amide] in type-2 diabetic patients may be exploited to pharmacologically lower their plasma glucose concentrations.
